Study of Cannabidiol in Sanfilippo Syndrome
Key facts
- Who runs it
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Where
- Torrance, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 35 people, planned
- Started
- 1 Apr 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Epidiolex
- Placebo
- Record updated
- 15 September 2026
Who can take part
- Age
- 4 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- MPS III diagnosis confirmed by genetic testing
- ≥ 4 years of age
- Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 16 years of age, assent must also be provided when cognitively possible
- If taking any of the following, no dose changes for the last 8 weeks:; Anakinra; Fluoxetine; Probiotic supplement
- One of the following criteria are met:; Previous participation in a gene/cell therapy or enzyme restorative clinical trial; Previously ineligible to participate in a gene/cell therapy or enzyme restorative clinical trial due to advanced disease state; Functional age, as measured by the Vineland, is ≤ 0.5 chronological age
Who cannot take part
- Concomitant use of any of the following therapies:; Rifampin; Diazepam (except for intermittent use as needed for treatment of a prolonged seizure episode); Clobazam; Stiripentol; Everolimus, sirolimus, tacrolimus; Digoxin; Valproate; Recreational or medical Tetrahydrocannabinol (THC) or synthetic cannabinoid medications (including Sativex) within the last three months; Felbamate (if taking for less than one year)
- Non-pharmacological therapies (e.g. ketogenic diet) must be stable for up to four weeks prior to enrollment
- Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study
- Mutation known to cause slowly progressive disease
- Known hypersensitivity to any components of Epidiolex (cannabidiol)
- Clinical evidence of liver disease or liver injury as indicated by the presence of abnormal tests (AST or ALT \> 2 x ULN; Bilirubin \> 2 x ULN)
- Equitable selection will be used when choosing participants. An individual who meets any of the following criteria will be excluded from participation in this study:
- Taken any form of cannabis, including cannabidiol, in the last 8 weeks
- Currently enrolled in another ongoing clinical trial
- Pregnant or lactating women
Where in United States
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, United StatesContact: Cristi WilliamsTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to test cannabidiol in Sanfilippo syndrome. The main questions it aims to answer are: 1) determine the safety of cannabidiol in Sanfilippo syndrome, and 2) explore the efficacy of cannabidiol in treating the neurobehavioral symptoms and functional outcomes of Sanfilippo syndrome.
Read full original descriptionShow less
Each participant's caregiver will be asked to complete surveys related to the participant's behavior, mood, sleep, stooling, pain, and caregiver stress intermittently throughout the study. All participants will be enrolled into one of two cohorts based on enrollment order:
1. Sentinel Safety Cohort (first 5 participants) - all participants treated with Epidiolex (cannabidiol) 2. Controlled Cohort (next 30 participants) - participants randomized 1:1 (equal chance) to start treatment with Epidiolex (cannabidiol) or placebo for 16 weeks, followed by an 8-week washout period (no treatment). Participants then switch to the opposite treatment group for 16 weeks followed by all participants treated for 52 weeks with Epidiolex (cannabidiol).
The 2 groups in the trial
- Epidiolex (cannabidiol)Treatment being tested
Oral Epidiolex (cannabidiol) administered twice daily (BID) Week 1: 5 mg/kg/day BID Weeks 2-8: 10 mg/kg/day BID Weeks 9-16: 20 mg/kg/day BID 8-week washout; cross-over to placebo comparator starting on Week 24.
Treatment: Epidiolex
- Placebo (PBO)Placebo, for comparison
Week 1: Dose escalate to maximum tolerated placebo dose Weeks 2-16: Maximum tolerated placebo dose 8-week washout; cross-over to Experimental group starting at week 24, following the same dose-escalation as the Experimental arm.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Effects of Cannabidiol on Neurobehavioral and Function Outcomes in Sanfilippo Syndrome
- Record updated
- 15 September 2026